Találati lista | Tudóstér

001-es BibID:	BIBFORM070012
035-os BibID:	e015874
Első szerző:	Márta Katalin
Cím:	High versus low energy administration in the early phase of acute pancreatitis (GOULASH trial) : protocol of a multicentre randomized double-blind clinical trial / Katalin Márta, Anikó Nóra Szabó, Dániel Pécsi, Péter Varjú, Judit Bajor, Szilárd Gódi, Patrícia Sarlós, Alexandra Mikó, Katalin Szemes, Mária Papp, Tamás Tornai, Áron Vincze, Zsolt Márton, Patrícia Anna Vincze, Erzsébet Lankó, Andrea Szentesi, Tímea Molnár, Roland Hagendorn, Faluhelyi Nándor, István Battyáni, Dezső Kelemen, Róbert Papp, Attila Miseta, Verzár Zsófia, Markus M. Lerch, Johan P. Neoptoleomos, Miklós Sain-Tóth, Ole H. Petersen, Peter Hegyi
Dátum:	2017
ISSN:	2044-6055
Megjegyzések:	Introduction. Acute pancreatitis (AP) is an inflammatory disease with no specific therapy. Mitochondrial injury followed by ATP depletion in both acinar and ductal cells is a recently discovered early event in the pathogenesis. Importantly, preclinical research showed that intracellular ATP delivery restores the physiological function of the cells and protects from cell injury suggesting that restoration of energy levels in the pancreas is therapeutically beneficial. Despite several, high quality and experimental observations in this area, no randomized trials have been conducted to date to address the requirements for energy intake in the early phase of AP. Methods/Design. This is a randomized, controlled two-arms double-blind multicentre trial. Patients suffering from AP will be randomly assigned to groups A (30 kcal/kg/day energy administration starting within 24h of hospital admission) or B (low energy administration during the first 72h of hospital admission). Energy will be delivered with nasoenteric tube feeding with additional intravenous glucose supplementation or total parenteral nutrition if necessary. A combination of multi organ failure for more than 48h and mortality is defined as the primary endpoint, whereas several secondary endpoints such as length of hospitalization or pain will be determined to elucidate more detailed differences between the groups. The general feasibility, safety and quality checks required for high quality evidence will be adhered to.Ethics and Dissemination. The study has been approved by the relevant organization, The Scientific and Research Ethics Committee of the Hungarian Medical Research Council (55961- 2/2016/EKU). This study will provide evidence whether early high-energy nutritional support is beneficial in the clinical management of AP. The results of this trial will be published in an open access way and disseminated among medical doctors.Trial registration: The trial has been registered at the ISRCTN (ISRTCN 63827758).
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban acute pancreatitis energy administration enteral feeding randomized clinical trial
Megjelenés:	BMJ Open. - 7 : 9 (2017), p. 1-9. -
További szerzők:	Szabó Anikó Nóra Pécsi Dániel Varjú Péter Bajor Judit Gódi Szilárd Sarlós Patrícia Mikó Alexandra Szemes Katalin Papp Mária (1975-) (belgyógyász, gasztroenterológus) Tornai Tamás István (1984-) (belgyógyász) Vincze Áron Márton Zsolt Vincze Patrícia Anna Lankó Erzsébet Szentesi Andrea Molnár Tímea Hágendorn Roland Faluhelyi Nándor Battyáni István Kelemen Dezső Papp Róbert Miseta Attila Verzár Zsófia Lerch, Markus M. Neoptoleomos, Johan P. Sain-Tóth, Miklós Petersen, Ole H. Hegyi Péter Jenő (belgyógyász)
Pályázati támogatás:	GINOP-2.3.2-15-2016-00015 GINOP KH-125678 NKFI
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM103700
035-os BibID:	(scopus)85121564971 (wos)000731322900016 (cikkazonosító)24158
Első szerző:	Ocskay Klementina
Cím:	Hypoalbuminemia affects one third of acute pancreatitis patients and is independently associated with severity and mortality / Ocskay Klementina, Vinkó Zsófia, Németh Dávid, Szabó László, Bajor Judit, Gódi Szilárd, Sarlós Patrícia, Czakó László, Izbéki Ferenc, Hamvas József, Papp Mária, Varga Márta, Török Imola, Mickevicius Artautas, Sallinen Ville, Maldonado Elena Ramirez, Galeev Shamil, Mikó Alexandra, Erőss Bálint, Imrei Marcell, Hegyi Péter Jenő, Faluhelyi Nándor, Farkas Orsolya, Kanizsai Péter, Miseta Attila, Nagy Tamás, Hágendorn Roland, Márton Zsolt, Szakács Zsolt, Szentesi Andrea, Hegyi Péter, Párniczky Andrea
Dátum:	2021
ISSN:	2045-2322
Megjegyzések:	The incidence and medical costs of acute pancreatitis (AP) are on the rise, and severe cases still have a 30% mortality rate. We aimed to evaluate hypoalbuminemia as a risk factor and the prognostic value of human serum albumin in AP. Data from 2461 patients were extracted from the international, prospective, multicentre AP registry operated by the Hungarian Pancreatic Study Group. Data from patients with albumin measurement in the frst 48 h (n= 1149) and anytime during hospitalization (n= 1272) were analysed. Multivariate binary logistic regression and Receiver Operator Characteristic curve analysis were used. The prevalence of hypoalbuminemia (<35 g/L) was 19% on admission and 35.7% during hospitalization. Hypoalbuminemia dose-dependently increased the risk of severity, mortality, local complications and organ failure and is associated with longer hospital stay. The predictive value of hypoalbuminemia on admission was poor for severity and mortality. Severe hypoalbuminemia (<25 g/L) represented an independent risk factor for severity (OR 48.761; CI 25.276?98.908) and mortality (OR 16.83; CI 8.32?35.13). Albumin loss during AP was strongly associated with severity (p< 0.001) and mortality (p= 0.002). Hypoalbuminemia represents an independent risk factor for severity and mortality in AP, and it shows a dose-dependent relationship with local complications, organ failure and length of stay.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Scientific Reports. - 11 : 1 (2021), p. 1-12. -
További szerzők:	Vinkó Zsófia Németh Dávid Szabó László Bajor Judit Gódi Szilárd Sarlós Patrícia Czakó László Izbéki Ferenc Hamvas József Papp Mária (1975-) (belgyógyász, gasztroenterológus) Varga Márta Török Imola Mickevicius, Artautas Sallinen, Ville Maldonado, Elena Ramirez Galeev, Shamil Mikó Alexandra Erőss Bálint Imrei Marcell Hegyi Péter Jenő (belgyógyász) Faluhelyi Nándor Farkas Orsolya Kanizsai Péter Miseta Attila Nagy Tamás Hágendorn Roland Márton Zsolt Szakács Zsolt Szentesi Andrea Hegyi Péter (pszichológus) Párniczky Andrea (gyermekgyógyász)
Pályázati támogatás:	EFOP-3.6.2-16-2017-00006 EFOP GINOP-2.3.2-15-2016-00015 GINOP
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM094178
035-os BibID:	(WOS)000727779500019 (Scopus)85106978919
Első szerző:	Szakó Lajos
Cím:	Early occurrence of pseudocysts in acute pancreatitis - A multicenter international cohort analysis of 2275 cases / Lajos Szakó, Noémi Gede, Alex Váradi, Benedek Tinusz, Nóra Vörhendi, Dóra Mosztbacher, Áron Vincze, Tamás Takács, László Czakó, Ferenc Izbéki, László Gajdán, Veronika Dunás-Varga, József Hamvas, Mária Papp, Krisztina Eszter Fehér, Márta Varga, Artautas Mickevicius, Imola Török, Klementina Ocskay, Márk Félix Juhász, Szilárd Váncsa, Nándor Faluhelyi, Orsolya Farkas, Attila Miseta, András Vereczkei, Alexandra Mikó, Péter Jenő Hegyi, Andrea Szentesi, Andrea Párniczky, Bálint Erőss, Péter Hegyi
Dátum:	2021
ISSN:	1424-3903
Megjegyzések:	BACKGROUND Pseudocysts being the most frequent local complications of acute pancreatitis (AP) have substantial effect on the disease course, hospitalization and quality of life of the patient. Our study aimed to understand the effects of pre existing (OLD-P) and newly developed (NEW-P) pseudocysts on AP. METHODS Data were extracted from the Acute Pancreatitis Registry organized by the Hungarian Pancreatic Study Group (HPSG). 2275 of 2461 patients had uploaded information concerning pancreatic morphology assessed by imaging technique. Patients were divided into "no pseudocyst" (NO-P) group, "old pseudocyst" (OLD-P) group, or "newly developed pseudocyst" (NEW-P) groups. RESULTS The median time of new pseudocyst development was nine days from hospital admission and eleven days from the beginning of the abdominal pain. More NEW-P cases were severe (15.9% vs 4.7% in the NO-P group p<0.001), with longer length of hospitalization (LoH) (median: 14 days versus 8 days, p<0.001), and were associated with several changed laboratory parameters. OLD-P was associated with male gender (72.2% vs. 56.1%, p=0.0014), alcoholic etiology (35.2% vs. 19.8% in the NO-P group), longer hospitalization (median: 10 days, p<0.001), a previous episode of AP (p<0.001), pre-existing diagnosis of chronic pancreatitis (CP) (p<0.001), current smoking (p<0.001), and increased alcohol consumption (unit/week) (p=0.014). CONCLUSION Most of the new pseudocysts develop within two weeks. Newly developing pseudocysts are associated with a more severe disease course and increased length of hospitalization. Pre-existing pseudocysts are associated with higher alcohol consumption and smoking. Because CP is more frequently associated with a pre-existing pseudocyst, these patients need closer attention after AP.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Pancreatology. - 21 : 6 (2021), p. 1161-1172. -
További szerzők:	Gede Noémi Váradi Alex (1991-) (biológus) Tinusz Benedek Vörhendi Nóra Mosztbacher Dóra Vincze Áron Takács Tamás (Szeged) Czakó László Izbéki Ferenc Gajdán László Dunás-Varga Veronika Hamvas József Papp Mária (1975-) (belgyógyász, gasztroenterológus) Fehér Krisztina Eszter Varga Márta Mickevicius, Artautas Török Imola Ocskay Klementina Juhász Márk Félix Váncsa Szilárd Faluhelyi Nándor Farkas Orsolya Miseta Attila Vereczkei András Mikó Alexandra Hegyi Péter Jr. (belgyógyász) Szentesi Andrea Párniczky Andrea (gyermekgyógyász) Erőss Bálint Hegyi Péter Jenő (belgyógyász)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM082674
Első szerző:	Zádori Noémi
Cím:	EarLy elimination of fatty acids iN hypertriglyceridemia-induced acuTe pancreatitis (ELEFANT trial) : protocol of an open-label, multicenter, adaptive randomized clinical trial / Noémi Zádori, Noémi Gede, Judit Antal, Andrea Szentesi, Hussain Alizadeh, Áron Vincze, Ferenc Izbéki, Mária Papp, László Czakó, Márta Varga, Enrique de-Madaria, Ole H. Petersen, Vijay P. Singh, Julia Mayerle, Nándor Faluhelyi, Attila Miseta, István Reiber, Péter Hegyi
Dátum:	2020
ISSN:	1424-3903
Megjegyzések:	Introduction: Acute pancreatitis (AP) is a life-threatening inflammatory disease, with no specific pharmacologi- cal treatment. However, concerning some etiologies, early specific intervention (such as ERCP in biliary AP) has proven to be remarkably beneficial. Hypertriglyceridemia (HTG) induces severe pancreatic damage by several direct (cellular damage) and indirect (deterioration of microcirculation) mechanisms. Published data suggest that early removal of triglycerides (TGs) and toxic free fatty acids (FFAs) may be advantageous; however, high-quality evidence is still missing in the literature. Methods: /Design: ELEFANT is a randomized controlled, multicenter, international trial testing the concept that early elimination of TGs and FFAs from the blood is beneficial in HTG-AP. The study will be performed with the adaptive "drop-the-loser" design, which supports the possibility of dropping the inferior treatment arm, based on the results of the interim analysis. Patients with HTG-AP defined by TG level over 11.3 mmol/l (1000 mg/dL) are randomized into three groups: (A) patients who undergo plasmapheresis and receive aggressive fluid resuscita- tion; (B) patients who receive insulin and heparin treatment with aggressive fluid resuscitation; and (C) patients with aggressive fluid resuscitation. Please note that all intervention must be started within 48 h from the onset of abdominal pain. Exclusion criteria are designed logically to decrease the possibility of any distorting effects of other diseases. The composite primary endpoint will include both severity and mortality.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Acute pancreatitis Hypertriglyceridemia Plasmapheresis Free fatty acids Heparin Insulin Randomized clinical trial
Megjelenés:	Pancreatology. - 20 : 3 (2020), p. 369-376. -
További szerzők:	Gede Noémi Antal Judit Szentesi Andrea Alizadeh, Hussain Vincze Áron Izbéki Ferenc Papp Mária (1975-) (belgyógyász, gasztroenterológus) Czakó László Varga Márta de-Madaria, Enrique Petersen, Ole H. Singh, Vijay P. Mayerle, Julia Faluhelyi Nándor Miseta Attila Reiber István Hegyi Péter (pszichológus)
Pályázati támogatás:	GINOP-2.3.2-15-2016-00048 GINOP KH-125678 Egyéb EFOP-3.6.2-16-2017-00006 EFOP LP2014-10/2014 Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: